Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.54 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | GPX4 | P36969 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17471261 | 0.83 | GRIA1 (0.50) | GRIA1GRIA3L3MBTL1POLBGRIA2 | |
| SCHEMBL3170099 | 0.80 | GRIA1 (0.46) | GRIA1GRIA3POLBGRIA2GRIA4 | |
| SCHEMBL3179817 | 0.77 | GRIA1 (0.44) | GRIA1GRIA3POLBGRIA2GRIA4 | |
| SCHEMBL15652402 | 0.76 | GRIA1 (0.43) | GRIA1GRIA3POLBGRIA2GRIA4 | |
| SCHEMBL30500337 | 0.76 | GRIA1 (0.43) | GRIA1GRIA3POLBGRIA2GRIA4 | |
| SCHEMBL3189524 | 0.76 | GRIA1 (0.43) | GRIA1GRIA3L3MBTL1GRIA2GRIA4 | |
| SCHEMBL3175475 | 0.72 | GRIA1 (0.38) | GRIA1GRIA3GRIA2GRIA4MAPK1 | |
| SCHEMBL8254522 | 0.71 | LMNA (0.43) | GRIA1GRIA3L3MBTL1KMT2AMEN1 | |
| SCHEMBL2676823 | 0.71 | MEN1 (0.41) | GRIA1GRIA3POLBKMT2AMEN1 | |
| SCHEMBL15651175 | 0.71 | ALDH1A1 (0.41) | GRIA1GRIA3GAAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | claimed |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | EDNRA, EDNRB, AGTR1 | GRIA1 201/4885GRIA3 394/4885L3MBTL1 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.